Company Description
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2005 |
| IPO Date | Jun 21, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 435 |
| CEO | John Shannon |
Contact Details
Address: 1375 West Fulton Street, Suite 1300 Chicago, Illinois 60607 United States | |
| Phone | 844 445 5704 |
| Website | xerispharma.com |
Stock Details
| Ticker Symbol | XERS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001867096 |
| CUSIP Number | 98422E103 |
| ISIN Number | US98422E1038 |
| Employer ID | 87-1082097 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Shannon | Chairman and Chief Executive Officer |
| Kevin McCulloch | President and Chief Operating Officer |
| Steven M. Pieper | Chief Financial Officer |
| Beth P. Hecht J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Anh T. Nguyen M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 1, 2026 | 144 | Filing |
| Sep 28, 2026 | 144 | Filing |
| Sep 9, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 144 | Filing |
| Aug 6, 2026 | 10-Q | Quarterly Report |
| Aug 6, 2026 | 8-K | Current Report |
| Jul 31, 2026 | SCHEDULE 13G | Filing |
| Jul 17, 2026 | 8-K | Current Report |
| Jul 7, 2026 | 144 | Filing |
| Jul 6, 2026 | 144 | Filing |